Microarray platforms are not a one-size-fits-all solution.
In molecular diagnostic assays, they fall into four functional categories, each purpose‑built to detect a specific class of genetic alteration. Multiple genotyping arrays interrogate known point mutations and SNPs, Comparative Genomic Hybridization (CGH) arrays scan for copy number changes, expression microarrays measure mRNA transcript levels, and resequencing microarrays offer targeted gene sequencing. Their target applications diverge accordingly: from high‑throughput carrier screening and pharmacogenetics, to cancer prognosis and hereditary risk assessment.
The classification of microarrays into genotyping, CGH, expression, and resequencing formats reflects a fundamental diagnostic principle: the detection technology must match the molecular event you need to find. Choosing the wrong category can lead to missed variants, ambiguous results, and wasted development resources. Understanding these boundaries is the first step to building a robust clinical assay.
The Four Functional Categories of Diagnostic Microarrays
These platform categories are defined by probe design and the type of genomic information they extract. Their clinical utility is directly tied to this specialization.
Multiple Genotyping Microarrays: Screening Known Variants
These are low‑density arrays engineered for simultaneous, multiplex detection of predefined mutations and single‑nucleotide polymorphisms (SNPs).
Target application: Carrier screening panels that require analyzing dozens to hundreds of specific sites—such as cystic fibrosis multi‑mutation panels—or pharmacogenetic drug‑sensitivity profiling where only known alleles matter.
Because the probes target known sequences, the assay delivers high specificity and rapid turnaround. However, it cannot detect novel or unlisted mutations outside the panel content.
Comparative Genomic Hybridization (CGH) Microarrays: Scanning Structural Changes
CGH arrays scan the entire genome for copy number variations—gene deletions, duplications, and amplifications.
Target application: Oncology, where identifying Her2/neu proto‑oncogene amplification guides targeted chemotherapy response. They also detect genomic imbalances in constitutional disorders and cancer prognosis.
These arrays do not rely on known variants; they compare test‑sample DNA against a reference to reveal structural imbalances. This makes them powerful for genome‑wide discovery of copy number changes, but they miss balanced rearrangements and small indels.
Expression Microarrays: Profiling Transcriptional Activity
Comprising immobilized complementary DNA probes on a chip substrate, expression microarrays measure mRNA transcript levels from biological samples.
Target application: Tumor staging and risk stratification in solid tumors, such as predicting malignancy potential in early‑stage breast cancer.
By capturing the dynamic snapshot of gene activity, these arrays help classify disease subtypes and forecast outcomes. Their data, however, reflects RNA abundance, not functional protein levels, and is sensitive to sample quality and degradation.
Resequencing Microarrays: Cost‑Effective Targeted Sequencing
Resequencing arrays are tailored as a lower‑cost alternative to full‑gene sequencing for large, clinically important target genes like BRCA1 and BRCA2.
Target application: High‑risk hereditary cancer screening where comprehensive reading of the gene’s coding region is required but whole‑genome sequencing is cost‑prohibitive.
They provide sequence‑level resolution within pre‑defined regions, enabling detection of both known and novel variants in those genes. Yet they remain restricted to the tiled genomic regions—deep intronic or off‑target mutations are missed.
Understanding the Trade‑Offs in Real‑World Use
Each functional category presents design constraints and practical limitations that diagnostic developers must evaluate.
Analytical blind spots. Genotyping arrays will not find mutations that aren’t on the panel. CGH cannot see balanced translocations. Expression signatures may not correlate perfectly with protein activity. Resequencing microarrays have a narrow genomic window. A clear understanding of the assay’s intended clinical question is essential to select the platform that minimizes the risk of false negatives.
Development and manufacturing complexity. The required raw materials and quality control demands differ sharply. Multiple genotyping arrays demand high‑purity, batch‑to‑batch consistent oligo probes for known targets. CGH platforms need robust reference DNA normalization. Expression arrays call for stringent RNA preservation and labeling protocols. Resequencing arrays require dense probe coverage and high‑fidelity hybridization. Each choice impacts regulatory validation timelines and cost.
Regulatory and workflow considerations. Low‑density genotyping panels often have simpler regulatory paths for IVD approval because they detect well‑characterized variants. CGH and expression microarrays, which generate complex probabilistic scores or copy number calls, may require additional clinical validation. Resequencing platforms must demonstrate accuracy comparable to Sanger or next‑generation sequencing for the target regions.
Making the Right Choice for Your Diagnostic Goal
Your selection must be driven by the molecular question your assay needs to answer. Align the platform category with the clinical need, and design your material and validation strategy accordingly.
- If your primary focus is carrier screening or pharmacogenetic profiling: Use multiple genotyping microarrays. They deliver high‑throughput, highly specific detection of known variants with a streamlined validation pathway.
- If your primary focus is cancer prognosis or targeted therapy selection: A CGH array can reveal copy‑number drivers like Her2/neu amplification; an expression array can yield transcriptional signatures for risk stratification. Choose based on whether the actionable biomarker is at the DNA or RNA level.
- If your primary focus is cost‑constrained hereditary cancer testing for large genes: Resequencing microarrays offer targeted sequence data for genes such as BRCA1/2 without the expense of whole‑genome sequencing, provided your clinical needs are limited to those loci.
- If your primary focus is discovery of novel structural variants across the genome: CGH arrays provide a genome‑wide screen for deletions and duplications, but be prepared to follow up with orthogonal methods to resolve breakpoints or confirm results.
Match the microarray’s functional design to the precise genetic alteration you seek—that alignment is what turns a benchtop reaction into a clinically actionable result.
Summary Table:
| Microarray Category | Target Genomic Event | Key Diagnostic Applications | Key Limitations |
|---|---|---|---|
| Multiple Genotyping | Known point mutations & SNPs | Carrier screening, pharmacogenetic profiling | Cannot detect novel variants outside panel |
| Comparative Genomic Hybridization (CGH) | Copy number variations (deletions, duplications) | Oncology (e.g., Her2/neu amplification), constitutional risk | Misses balanced translocations and small indels |
| Expression Microarrays | mRNA transcript levels | Tumor staging, risk stratification in solid tumors | Sensitive to RNA quality; reflects RNA not protein |
| Resequencing Microarrays | Sequence-level targeted gene reading | Cost-effective hereditary cancer screening (BRCA1/2) | Restricted only to pre-defined tiled genomic regions |
Accelerate Your Diagnostic Assay Development with CamelBio
Selecting the right microarray format is only the first step—ensuring high batch-to-batch consistency, probe purity, and seamless validation is critical to commercial success. CamelBio provides diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and specialized consulting, supporting your pipeline from initial concept to clinic.
Looking to optimize your molecular diagnostic workflows or source reliable IVD raw materials? Contact CamelBio today to collaborate with our technical experts.